Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Department of Urology, Shanghai General Hospital of Nanjing Medical University, Shanghai, China.
Front Immunol. 2022 Jul 22;13:869297. doi: 10.3389/fimmu.2022.869297. eCollection 2022.
Clear Cell Renal Carcinoma (ccRCC) accounts for nearly 80% of renal carcinoma cases, and immunotherapy plays an important role in ccRCC therapy. However, the responses to immunotherapy and overall survival for ccRCC patients are still hard to predict. Here, we constructed an immune-related predictive signature using 19 genes based on TCGA datasets. We also analyzed its relationships between disease prognosis, infiltrating immune cells, immune subtypes, mutation load, immune dysfunction, immune escape, etc. We found that our signature can distinguish immune characteristics and predict immunotherapeutic response for ccRCC patients with better prognostic prediction value than other immune scores. The expression levels of prognostic genes were determined by RT-qPCR assay. This signature may help to predict overall survival and guide the treatment for patients with ccRCC.
透明细胞肾细胞癌 (ccRCC) 占肾细胞癌病例的近 80%，免疫疗法在 ccRCC 治疗中起着重要作用。然而，ccRCC 患者对免疫治疗的反应和总生存率仍然难以预测。在这里，我们使用基于 TCGA 数据集的 19 个基因构建了一个免疫相关的预测特征。我们还分析了其与疾病预后、浸润免疫细胞、免疫亚型、突变负荷、免疫功能障碍、免疫逃逸等的关系。我们发现，我们的特征可以区分免疫特征，并预测 ccRCC 患者的免疫治疗反应，其预后预测价值优于其他免疫评分。预后基因的表达水平通过 RT-qPCR 检测确定。该特征可能有助于预测总生存率并指导 ccRCC 患者的治疗。
Zotero 插件
